Synonyms: BMS-986016 | BMS986016 | ONO-4482 | Opdualag® (nivolumab + relatlimab-rmbw) | relatlimab-rmbw
relatlimab is an approved drug (EMA & FDA (2022))
Compound class:
Antibody
Comment: Relatlimab (BMS-986016) is an anti-LAG3 monoclonal antibody that was developed for utility in cancer immunotherapy.
|
Classification ![]() |
|
Compound class | Antibody |
Ligand families/groups | Immune checkpoint modulators |
Approved drug? | Yes (EMA & FDA (2022)) |
Approved drug? | Yes. EMA (2022) | FDA (2022) |
International Nonproprietary Names ![]() |
|
INN number | INN |
10735 | relatlimab |
Synonyms ![]() |
BMS-986016 | BMS986016 | ONO-4482 | Opdualag® (nivolumab + relatlimab-rmbw) | relatlimab-rmbw |
Database Links ![]() |
|
Specialist databases | |
IMGT/mAb-DB | 781 |
Other databases | |
GtoPdb PubChem SID | 336446922 |
Search PubMed clinical trials | relatlimab |
Search PubMed titles | relatlimab |
Search PubMed titles/abstracts | relatlimab |